VivoSeq
Other

Stereotactic Radiation

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Stereotactic Radiation is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

75/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Terminated2 · 50%
Withdrawn1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Withdrawn·MMedical University of South Carolina·Phase 2·NCT03149159
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT01324635·17 enrolled
Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases
Terminated·CCentre Leon Berard·Phase 2·NCT04094077·1 enrolled
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Recruiting·BBaptist Health South Florida·Phase 1/2·NCT05789589·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)